Sun, Sep 14, 2014, 11:01 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

ADVANCED CELL TECH Message Board

dojon31 3 posts  |  Last Activity: Sep 12, 2014 11:03 AM Member since: Dec 7, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Will Schwartz do the honours ?

    by dojon31 Sep 12, 2014 8:38 AM
    dojon31 dojon31 Sep 12, 2014 11:03 AM Flag

    Doctor Schwarz is the principle investigator in each of ACT’s stem cell based eye trials.The Jules Stein Eye Institute, where he’s chief of the retina division, and its reputation has most likely opened the door for the rest of the top class investigators, so they more or less owe him the scope.

    His presentation is colliding with the general expectation that results will be published close to the RS, in order to avoid a total sell off.
    The companies communication that RS, revealing of the trial data and the up listing will happen in a small time frame.

    I understand that the company has no saying on whether an article (trial data communication) will be published or not in an renowned scientific journal, but if there is an consensus to publish I find it hard to believe that the company has no impact at all on when the data will be published.
    Although the company kept on using this as an excuse for not sharing the results, I think other matters (legal issues, a proper CEO…)still had to be tackled. That is, in mine opinion why Schwarz had to hold back in the past.

    And to be honest I’m tired of waiting.

  • today at 17.03 at the Euretina congress in London? “Stem cell therapy for retinal disease”?

    On two previous scientific meetings this year he has sent a replacement, because he couldn’t disclose data at that time?

    Embargo Policy

    Like most medical journals, NEJM employs a media embargo system. NEJM content is made available on the Friday before publication to qualifying journalists who agree not to publish stories before Wednesday at 5PM Eastern time. There are two fundamental reasons for our embargo: it allows the media time to report accurately on complex and important new research findings, and it allows print subscribers to read and understand the full reports in NEJM before media reports on them appear, which often leads patients to ask their physicians for interpretation and guidance.

    A special embargo period is established for online first articles and articles released in conjunction with medical meetings. The timing and length of this period is variable depending on production schedules.

    Medical Meetings and Government Oversight

    Presenting research at a scientific meeting or submitting results to a government oversight board prior to publication does not violate NEJM’s policies.

  • dojon31 dojon31 Aug 11, 2014 4:48 PM Flag

    Nice find
    Hope it's finally happening

    Sentiment: Buy

ACTC
0.08150.0000(0.00%)Aug 27 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
21Vianet Group, Inc.
NasdaqGSFri, Sep 12, 2014 4:00 PM EDT